How research is judged

What does Insufficient evidence mean?

A valid conclusion when sources are absent, too narrow, inconsistent, or indirect. ¹

Also called: limited evidence, not enough evidence, unclear evidence

Simple definition

Insufficient evidence, in plain English

A valid conclusion when sources are absent, too narrow, inconsistent, or indirect. ¹

Why it matters

How this word is used in cannabinoid research

This term tells you what kind of research you are reading. It helps separate stronger human evidence from early or indirect evidence.

How to read it

Use the term to understand the study, then open the source before drawing a conclusion.

Common questions

Questions people ask

What does Insufficient evidence mean?

A valid conclusion when sources are absent, too narrow, inconsistent, or indirect.

Why does Insufficient evidence matter?

This term tells you what kind of research you are reading. It helps separate stronger human evidence from early or indirect evidence.

Is Insufficient evidence proof that a cannabinoid works?

No. A definition helps explain the language. The related research pages and their sources show what was actually studied.

Sources

Research connected to this term

Definitions explain the word. These links show research records currently connected with it.

1
Cannabinol and Sleep: Separating Fact from Fiction insufficient PubMed 34468204
2
Using Cannabis and CBD to Sleep: An Updated Review. insufficient PubMed 39612156
3
Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. insufficient PubMed 37612115
4
Cannabinoids, Insomnia, and Other Sleep Disorders. insufficient PubMed 35537535
5
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. insufficient PubMed 36206805
6
Cannabidiol's impact on drug-metabolization. insufficient PubMed 37541924

See all 487 connected research sources

1
Cannabinol and Sleep: Separating Fact from Fiction insufficient PubMed 34468204
2
Using Cannabis and CBD to Sleep: An Updated Review. insufficient PubMed 39612156
3
Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. insufficient PubMed 37612115
4
Cannabinoids, Insomnia, and Other Sleep Disorders. insufficient PubMed 35537535
5
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. insufficient PubMed 36206805
6
Cannabidiol's impact on drug-metabolization. insufficient PubMed 37541924
7
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. insufficient PubMed 35156171
8
Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review. insufficient PubMed 33497784
9
Cannabis and driving ability. insufficient PubMed 33839427
10
Association of driving with blood delta-9-tetrahydrocannabinol: a systematic review. insufficient PubMed 40172477
11
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. insufficient PubMed 33424664
12
Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. insufficient PubMed 39598860
13
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. insufficient PubMed 21749363
14
The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. insufficient PubMed 40270953
15
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. insufficient PubMed 32899626
16
Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder. insufficient PubMed 33895189
17
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol. insufficient PubMed 32335286
18
Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies. insufficient PubMed 32825313
19
Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. insufficient PubMed 30627539
20
Investigational cannabinoids in seizure disorders, what have we learned thus far? insufficient PubMed 29842819
21
Memantine for autism spectrum disorder. insufficient PubMed 36006807
22
Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. insufficient PubMed 39007525
23
Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. insufficient PubMed 39854828
24
Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. insufficient PubMed 31288397
25
Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. insufficient PubMed 32918835
26
Pharmacotherapies for cannabis use disorder. insufficient PubMed 41025421
27
Mechanisms of cannabis impairment: Implications for modeling driving performance. insufficient PubMed 34634690
28
Prescribing medicinal cannabis. insufficient PubMed 33093741
29
Driving Impairment Cases Involving Etizolam and Flubromazolam. insufficient PubMed 32399568
30
Therapeutic Use of Cannabis and Cannabinoids: A Review. insufficient PubMed 41296368
31
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. insufficient PubMed 35982439
32
The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. insufficient PubMed 33998900
33
Applications of Cannabinoids in Neuropathic Pain: An Updated Review. insufficient PubMed 37824417
34
Acidic Cannabinoids Suppress Proinflammatory Cytokine Release by Blocking Store-operated Calcium Entry. insufficient PubMed 35910331
35
Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. insufficient PubMed 31899693
36
Therapeutic potential of acidic cannabinoids: an update. insufficient PubMed 41545891
37
CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant). insufficient PubMed 21740450
38
Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review. insufficient PubMed 42339654
39
Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? insufficient PubMed 33613289
40
Semiquantitative Screening of THC Analogues by Silica Gel TLC with an Ag(I) Retention Zone and Chromogenic Smartphone Detection. insufficient PubMed 36178203
41
Identification and Quantification of the Main Psychoactive Ingredients of Cannabis in Urine Using Excitation-Eemission Matrix Fluorescence Coupled with Parallel Factor Analysis. insufficient PubMed 37810707
42
Ultrafast, Selective, and Highly Sensitive Nonchromatographic Analysis of Fourteen Cannabinoids in Cannabis Extracts, Δ8-Tetrahydrocannabinol Synthetic Mixtures, and Edibles by Cyclic Ion Mobility Spectrometry-Mass Spectrometry. insufficient PubMed 38862388
43
Quality Control of Traditional Cannabis Tinctures: Pattern, Markers, and Stability. insufficient PubMed 28117322
44
Pharmacologic treatment of fibromyalgia: an update. insufficient PubMed 41142233
45
The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories. insufficient PubMed 21845389
46
Cannabis-based medicines for chronic neuropathic pain in adults. insufficient PubMed 41548880
47
Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey. insufficient PubMed 40708053
48
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. insufficient PubMed 37648266
49
High Stakes: Exploring the Impact of Cannabis Use in Pregnancy and Lactation. insufficient PubMed 40164212
50
Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding. insufficient PubMed 35903331
51
Risks of Cannabinoid Exposure on Birth Outcomes: A Systematic Review. insufficient PubMed 40589083
52
Management of Pediatric Cannabinoid Hyperemesis Syndrome: A Review. insufficient PubMed 34035677
53
Cannabis Use in Pregnancy and Neonatal Outcomes: A Systematic Review and Meta-Analysis. insufficient PubMed 36730710
54
Association of Cannabis with Apneic Episodes in a Breastfed Infant: A Case Study. insufficient PubMed 38469628
55
Phytocannabinoids and epilepsy. insufficient PubMed 25475762
56
Antiepileptic Drugs in Clinical Development: Differentiate or Die? insufficient PubMed 28799516
57
The potential role of cannabinoids in epilepsy treatment. insufficient PubMed 28845714
58
Cannabinoids for epilepsy: What do we know and where do we go? insufficient PubMed 29214639
59
Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review. insufficient PubMed 39541799
60
Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting. insufficient PubMed 34115951
61
Short term feeding of industrial hemp with a high cannabidiolic acid (CBDA) content increases lying behavior and reduces biomarkers of stress and inflammation in Holstein steers. insufficient PubMed 35256692
62
Medical Cannabis Use and Inflammatory Cytokines and Chemokines Among Adult Chronic Pain Patients. insufficient PubMed 36342776
63
Raman-Based Differentiation of Hemp, Cannabidiol-Rich Hemp, and Cannabis. insufficient PubMed 32401504
64
Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sativa extract in beagles. insufficient PubMed 32735381
65
Phytochemical Analysis of the Methanolic Extract and Essential Oil from Leaves of Industrial Hemp Futura 75 Cultivar: Isolation of a New Cannabinoid Derivative and Biological Profile Using Computational Approaches. insufficient PubMed 35807623
66
(‒)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research. insufficient PubMed 32517131
67
Effects of Cannabidiol on Locomotor Activity. insufficient PubMed 35629320
68
Synergy between cannabidiol, cannabidiolic acid, and Δ⁹-tetrahydrocannabinol in the regulation of emesis in the Suncus murinus (house musk shrew). insufficient PubMed 26030435
69
Alginate-based microencapsulation as a strategy to improve the therapeutic potential of cannabidiolic acid. insufficient PubMed 39667593
70
Self-reported adverse events associated with ∆8-Tetrahydrocannabinol (Delta-8-THC) Use. insufficient PubMed 37217977
71
Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. insufficient PubMed 38868665
72
Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review. insufficient PubMed 39805119
73
Prevalence of carboxy-Δ8-tetrahydrocannabiniol in antidoping samples. insufficient PubMed 38176407
74
Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. insufficient PubMed 36742440
75
Cannabinoids in clinical practice. insufficient PubMed 11152013
76
Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system. insufficient PubMed 40206058
77
The Potential of Cannabichromene (CBC) as a Therapeutic Agent. insufficient PubMed 38777605
78
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. insufficient PubMed 40872492
79
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. insufficient PubMed 37630401
80
A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics. insufficient PubMed 38229238
81
CBD, a precursor of THC in e-cigarettes. insufficient PubMed 33903673
82
Cannabis use during pregnancy: Pharmacokinetics and effects on child development. insufficient PubMed 28847562
83
Impact of cannabinoids on pregnancy, reproductive health, and offspring outcomes. insufficient PubMed 35662548
84
Cannabis and synaptic reprogramming of the developing brain. insufficient PubMed 34021274
85
Long-term Cognitive, Psychological, and Health Outcomes Associated With Child Abuse and Neglect. insufficient PubMed 32943535
86
[Consequences of tobacco, cocaine and cannabis consumption during pregnancy on the pregnancy itself, on the newborn and on child development: A review]. insufficient PubMed 25439854
87
Smoke Alarm. insufficient PubMed 37651516
88
Maternal cannabis use in pregnancy, perinatal outcomes, and cognitive development in offspring: a longitudinal analysis of the ALSPAC cohort using paternal cannabis use as a negative control exposure. insufficient PubMed 40353977
89
Longitudinal Associations Between Cannabis Use during Pregnancy and Child Cognitive, Motor, and Language Development at 2 Years Old. insufficient PubMed 40121379
90
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. insufficient PubMed 33754312
91
An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents. insufficient PubMed 42057496
92
Marijuana and the Pediatric Population. insufficient PubMed 32661188
93
Pediatric Concerns Due to Expanded Cannabis Use: Unintended Consequences of Legalization. insufficient PubMed 27139708
94
Recreational Cannabis Use During Human Pregnancy: Its Effects on the Placenta and Endocannabinoid System. insufficient PubMed 41683846
95
Cannabinoid Signalling in Immune-Reproductive Crosstalk during Human Pregnancy. insufficient PubMed 33800053
96
Cannabis for morning sickness: areas for intervention to decrease cannabis consumption during pregnancy. insufficient PubMed 37330589
97
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. insufficient PubMed 30374683
98
Update on Cannabidiol in Drug-Resistant Epilepsy. insufficient PubMed 39585547
99
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment. insufficient PubMed 31802404
100
Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. insufficient PubMed 33667843
101
Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program. insufficient PubMed 37593907
102
Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids. insufficient PubMed 36257598
103
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. insufficient PubMed 17828291
104
Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. insufficient PubMed 25220897
105
Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024). insufficient PubMed 39288632
106
Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. insufficient PubMed 18537620
107
Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding. insufficient PubMed 31146657
108
Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55. insufficient PubMed 30670965
109
Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors. insufficient PubMed 28826536
110
New Insights in Cannabinoid Receptor Structure and Signaling. insufficient PubMed 30767756
111
Cannabinoid Ligands Targeting TRP Channels. insufficient PubMed 30697147
112
An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors. insufficient PubMed 33362478
113
Cannabis Use and the Risk for Psychosis and Affective Disorders. insufficient PubMed 31647377
114
Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies. insufficient PubMed 42309106
115
Cannabis and psychiatric disorders. insufficient PubMed 20562767
116
Role of cannabis in cardiovascular disorders. insufficient PubMed 28840009
117
Short-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise. insufficient PubMed 39630203
118
Clinical management of cannabis withdrawal. insufficient PubMed 34791767
119
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. insufficient PubMed 35510826
120
The differential effects of medicinal cannabis on mental health: A systematic review. insufficient PubMed 40186931
121
Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. insufficient PubMed 38562466
122
Diagnosis and Management of Cyclic Vomiting Syndrome: A Critical Review. insufficient PubMed 36791365
123
Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. insufficient PubMed 38478773
124
Cannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviews. insufficient PubMed 29168289
125
Cannabinoids and monoaminergic system: implications for learning and memory. insufficient PubMed 39206116
126
Prenatal cannabinoid exposure and altered neurotransmission. insufficient PubMed 30771373
127
Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. insufficient PubMed 26858214
128
Endocannabinoid signaling and long-term synaptic plasticity. insufficient PubMed 19575681
129
Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies. insufficient PubMed 42076122
130
[Not all drugs are the same]. insufficient PubMed 23974649
131
Brands of Intoxicating Cannabis Products in Vape Shops: United States, 2023. insufficient PubMed 41324909
132
Calculated and experimental 1 H and 13 C NMR assignments for cannabicitran. insufficient PubMed 34617621
133
Isolation and Characterization of Impurities in Commercially Marketed Δ8-THC Products. insufficient PubMed 36827690
134
Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. insufficient PubMed 38885660
135
Synthetic Strategies for Rare Cannabinoids Derived from Cannabis sativa. insufficient PubMed 35648593
136
Chiral Separation of Cannabichromene, Cannabicyclol, and Their Acidic Analogs on Polysaccharide Chiral Stationary Phases. insufficient PubMed 36770831
137
Cannabichromene Racemization and Absolute Stereochemistry Based on a Cannabicyclol Analog. insufficient PubMed 34078070
138
A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. insufficient PubMed 38940871
139
Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments. insufficient PubMed 33522084
140
A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors. insufficient PubMed 39657242
141
Cannabidiol: Pharmaceutical formulations and biomedical applications. insufficient PubMed 42212209
142
Cys-loop receptors on cannabinoids: All high? insufficient PubMed 36439263
143
Allosteric modulation of glycine receptors. insufficient PubMed 21557733
144
Sampling glutamate and GABA with microdialysis: suggestions on how to get the dialysis membrane closer to the synapse. insufficient PubMed 15589342
145
Cannabinoids in Parkinson's Disease. insufficient PubMed 28861502
146
Tolerance to alcohol: A critical yet understudied factor in alcohol addiction. insufficient PubMed 33631255
147
Pharmacokinetics and pharmacodynamics of cannabinoids. insufficient PubMed 12648025
148
CB2 receptor in the CNS: From immune and neuronal modulation to behavior. insufficient PubMed 37164044
149
Cannabinoid receptor signaling. insufficient PubMed 16596771
150
Pharmacokinetics of Non-Psychotropic Phytocannabinoids. insufficient PubMed 40006604
151
Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus. insufficient PubMed 32824356
152
Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae. insufficient PubMed 39808700
153
In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. insufficient PubMed 35306000
154
Bidimensional heart-cut achiral-chiral liquid chromatography coupled to high-resolution mass spectrometry for the separation of the main chiral phytocannabinoids and enantiomerization studies of cannabichromene and cannabichromenic acid. insufficient PubMed 37708768
155
Comparison of decarboxylation rates of acidic cannabinoids between secretory cavity contents and air-dried inflorescence extracts in Cannabis sativa cv. 'Cherry Wine'. insufficient PubMed 39013926
156
Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures. insufficient PubMed 35566314
157
An Introduction to the Endogenous Cannabinoid System. insufficient PubMed 26698193
158
The Endocannabinoid System and its Modulation by Phytocannabinoids. insufficient PubMed 26271952
159
Endocannabinoid Turnover. insufficient PubMed 28826539
160
Endocannabinoids. insufficient PubMed 9831287
161
Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. insufficient PubMed 19833407
162
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. insufficient PubMed 17704824
163
Classical endocannabinoid-like compounds and their regulation by nutrients. insufficient PubMed 24677570
164
Effects of fermentation and alkalisation on the formation of endocannabinoid-like compounds in olives. insufficient PubMed 38909454
165
Endocannabinoids, endocannabinoid-like compounds and cortisone in head hair of health care workers as markers of stress and resilience during the early COVID-19 pandemic. insufficient PubMed 38296973
166
Roles of Endocannabinoids and Endocannabinoid-Like Molecules in Energy Homeostasis and Metabolic Regulation: A Nutritional Perspective. insufficient PubMed 34115519
167
Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. insufficient PubMed 32203086
168
The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? insufficient PubMed 34217798
169
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. insufficient PubMed 20047159
170
Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review. insufficient PubMed 34959715
171
Critical enzymes involved in endocannabinoid metabolism. insufficient PubMed 17346227
172
Chemical Probes for Investigating the Endocannabinoid System. insufficient PubMed 39747798
173
Structural properties and role of the endocannabinoid lipases ABHD6 and ABHD12 in lipid signalling and disease. insufficient PubMed 30564946
174
The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. insufficient PubMed 21418147
175
Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? insufficient PubMed 17005273
176
Cardiovascular consequences of marijuana use. insufficient PubMed 12412838
177
Acute Effects of Cannabis Inhalation on Arterial Stiffness, Vascular Endothelial Function, and Cardiac Function. insufficient PubMed 39575727
178
Cannabis use and acute coronary syndrome. insufficient PubMed 30964363
179
Endocannabinoids, blood pressure and the human heart. insufficient PubMed 18426501
180
Statewide Variation in Cannabinoid Regulations. insufficient PubMed 36848540
181
Cannabis Contaminants Limit Pharmacological Use of Cannabidiol. insufficient PubMed 33013414
182
Pesticides and trace elements in cannabis: Analytical and environmental challenges and opportunities. insufficient PubMed 31471034
183
Cautious Hope for Cannabidiol (CBD) in Rheumatology Care. insufficient PubMed 32144889
184
Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. insufficient PubMed 27683558
185
Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol (CBD) products. insufficient PubMed 35987236
186
Cannabidiol Gummy Products: LC-MS/MS Assessment of Cannabinoid Concentrations. insufficient PubMed 40454463
187
Acid-Catalyzed Conversion of Cannabidiol to Tetrahydrocannabinols: En Route to Demystifying Manufacturing Processes and Controlling the Reaction Outcomes. insufficient PubMed 40250991
188
Delta-8 tetrahydrocannabinol: a scoping review and commentary. insufficient PubMed 36710464
189
The potential role of cannabinoids in dermatology. insufficient PubMed 31599175
190
Cannabis and the skin. insufficient PubMed 34785006
191
Cannabinoids and Their Receptors in Skin Diseases. insufficient PubMed 38003712
192
Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science. insufficient PubMed 41008526
193
Cannabis sativa and Skin Health: Dissecting the Role of Phytocannabinoids. insufficient PubMed 33851375
194
Potential of cannabidiol as acne and acne scar treatment: novel insights into molecular pathways of pathophysiological factors. insufficient PubMed 38904694
195
Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation. insufficient PubMed 33909195
196
The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. insufficient PubMed 30138623
197
Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations. insufficient PubMed 36439142
198
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. insufficient PubMed 19608284
199
Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America's Poison Centers. insufficient PubMed 38686923
200
Delta-8 THC Retail Availability, Price, and Minimum Purchase Age. insufficient PubMed 36342930
201
A Survey Study of Individuals Using Hexahydrocannabinol Cannabis Products: Use Patterns and Perceived Effects. insufficient PubMed 37934167
202
Temperature-sensitive transient receptor potential vanilloid channels: structural insights into ligand-dependent activation. insufficient PubMed 33155670
203
The Pharmacological Case for Cannabigerol. insufficient PubMed 33168643
204
Pharmacological effects of cannabidiol by transient receptor potential channels. insufficient PubMed 35483477
205
Cannabinoids in the landscape of cancer. insufficient PubMed 34259916
206
Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. insufficient PubMed 18354058
207
Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. insufficient PubMed 36912195
208
Metabolism and liver toxicity of cannabidiol. insufficient PubMed 38904421
209
Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review. insufficient PubMed 39228144
210
The Psychiatric Consequences of Cannabinoids. insufficient PubMed 29678279
211
Pharmacotherapies for cannabis dependence. insufficient PubMed 30687936
212
Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. insufficient PubMed 32271390
213
Regulation of nausea and vomiting by cannabinoids. insufficient PubMed 21175589
214
Cannabinoids: the lows and the highs of chemotherapy-induced nausea and vomiting. insufficient PubMed 30720344
215
Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting. insufficient PubMed 27507945
216
Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders. insufficient PubMed 33332006
217
Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. insufficient PubMed 36417631
218
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies. insufficient PubMed 36194365
219
CBD in the Treatment of Epilepsy. insufficient PubMed 38731471
220
Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies. insufficient PubMed 37655228
221
Cannabis-based medicines for chronic neuropathic pain in adults. insufficient PubMed 29513392
222
Cannabis-Based Products for Chronic Pain : An Updated Systematic Review. insufficient PubMed 41429020
223
Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials. insufficient PubMed 33561282
224
Cannabinoids: Medical implications. insufficient PubMed 26912385
225
Cannabinoids as a Natural Alternative for the Management of Neuropathic Pain: A Systematic Review of Randomized Placebo-Controlled Trials. insufficient PubMed 39445260
226
The Effects of Cannabinoids on Sleep. insufficient PubMed 35459406
227
Effectiveness of cannabinoids on subjective sleep quality in people with and without insomnia or poor sleep: A systematic review and meta-analysis of randomised studies. insufficient PubMed 40929927
228
The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. insufficient PubMed 41856154
229
Should Oncologists Recommend Cannabis? insufficient PubMed 31161270
230
Cannabis dosing and administration for sleep: a systematic review. insufficient PubMed 36107800
231
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. insufficient PubMed 38427284
232
State-of-the-art management of Dravet syndrome. insufficient PubMed 40836583
233
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. insufficient PubMed 37695433
234
Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome. insufficient PubMed 40072476
235
Treatment of Dravet Syndrome. insufficient PubMed 27264138
236
Current and emerging pharmacotherapies in Lennox-Gastaut syndrome. insufficient PubMed 40468679
237
Anti-seizure medications for Lennox-Gastaut syndrome. insufficient PubMed 33825230
238
Lennox-Gastaut syndrome: New treatments and treatments under investigation. insufficient PubMed 32409177
239
Management of Lennox-Gastaut syndrome beyond childhood: A comprehensive review. insufficient PubMed 33243685
240
Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. insufficient PubMed 39299947
241
Cannabis and Mental Health: A Review. insufficient PubMed 41801216
242
Association of cannabis potency with mental ill health and addiction: a systematic review. insufficient PubMed 35901795
243
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. insufficient PubMed 33228239
244
High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review. insufficient PubMed 40854216
245
Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. insufficient PubMed 31672337
246
Cardiovascular system effects of marijuana. insufficient PubMed 12412837
247
Cannabinoids and the heart-a psychiatrist's perspective. insufficient PubMed 39331072
248
The acute cardiovascular response to dynamic exercise and recovery following cannabis use. insufficient PubMed 41115058
249
At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. insufficient PubMed 22503477
250
A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of Δ⁸-Tetrahydrocannabinol. insufficient PubMed 29385080
251
Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. insufficient PubMed 19367504
252
[Cannabis use and cannabis use disorders]. insufficient PubMed 39134752
253
Pharmacotherapies for cannabis dependence. insufficient PubMed 25515775
254
Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. insufficient PubMed 36434879
255
Developing a phone-based measure of impairment after acute oral ∆9-tetrahydrocannabinol. insufficient PubMed 31407943
256
Acute effects of naturalistic THC vs. CBD use on recognition memory: a preliminary study. insufficient PubMed 33526107
257
Effects of different methods of cannabis use on cognition and blood THC: A systematic review. insufficient PubMed 40368229
258
[Cannabis: Similarities and differences with tobacco]. insufficient PubMed 32381378
259
The acute effects of cannabis on human executive function. insufficient PubMed 30199388
260
Pharmacology of Medical Cannabis. insufficient PubMed 31332738
261
Cannabis-based medicines and medical cannabis for adults with cancer pain. insufficient PubMed 37283486
262
Cannabis-Based Products for Chronic Pain : A Systematic Review. insufficient PubMed 35667066
263
Practical considerations in medical cannabis administration and dosing. insufficient PubMed 29307505
264
Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain. insufficient PubMed 34802112
265
Cannabinoids: Therapeutic Use in Clinical Practice. insufficient PubMed 35328765
266
Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics. insufficient PubMed 27274310
267
The Risk of QTc Prolongation with Antiemetics in the Palliative Care Setting: A Narrative Review. insufficient PubMed 33974499
268
Chemotherapy-induced nausea and vomiting. insufficient PubMed 18391612
269
[Dronabinol (delta9-tetrahydrocannabinol) in long-term treatment. Symptom control in patients with multiple sclerosis and spasticity, neuropathic pain, loss of appetite and cachexia]. insufficient PubMed 23570087
270
Cancer cachexia and cannabinoids. insufficient PubMed 10575285
271
Orexigenic and anabolic agents. insufficient PubMed 12608509
272
Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. insufficient PubMed 29670357
273
Systematic review and meta-analysis of cannabinoids in palliative medicine. insufficient PubMed 29400010
274
Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS. insufficient PubMed 26929669
275
Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. insufficient PubMed 15050664
276
The cancer cachexia syndrome. insufficient PubMed 9208884
277
Cannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis. insufficient PubMed 33244728
278
Use of Cannabidiol in the Management of Insomnia: A Systematic Review. insufficient PubMed 36149724
279
Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. insufficient PubMed 32603954
280
Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes. insufficient PubMed 38924151
281
[Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences]. insufficient PubMed 27428345
282
Review of NIOSH Cannabis-Related Health Hazard Evaluations and Research. insufficient PubMed 32053725
283
Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes. insufficient PubMed 36228902
284
Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. insufficient PubMed 40967679
285
Pharmacological actions of cannabinoids. insufficient PubMed 16596770
286
Molecular Pharmacology of Phytocannabinoids. insufficient PubMed 28120231
287
The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis. insufficient PubMed 10036999
288
Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use. insufficient PubMed 38673788
289
Cannabinoids, inflammation, and fibrosis. insufficient PubMed 27435265
290
Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish. insufficient PubMed 36424484
291
[Marijuana--2000]. insufficient PubMed 11367861
292
Cannabis: Chemistry, extraction and therapeutic applications. insufficient PubMed 34838836
293
Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice. insufficient PubMed 39699828
294
Non-psychotropic cannabinoids as inhibitors of TET1 protein. insufficient PubMed 35462234
295
Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis. insufficient PubMed 40326034
296
Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma. insufficient PubMed 33562819
297
Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? insufficient PubMed 37414155
298
The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling. insufficient PubMed 36497400
299
Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects. insufficient PubMed 42352060
300
Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. insufficient PubMed 32628766
301
Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges. insufficient PubMed 42105814
302
Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. insufficient PubMed 39003387
303
The Origin and Biomedical Relevance of Cannabigerol. insufficient PubMed 35887277
304
Cannabinoid hyperemesis syndrome. insufficient PubMed 22150623
305
The Pharmacology of Cannabinoids in Chronic Pain. insufficient PubMed 40046175
306
Acute Cannabigerol Administration Lowers Blood Pressure in Mice. insufficient PubMed 35615681
307
Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action. insufficient PubMed 35614947
308
Cannabigerol and cannabichromene in Cannabis sativa L. insufficient PubMed 36654096
309
The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis. insufficient PubMed 29562280
310
Development of a Rapid LC-MS/MS Method for the Quantification of Cannabidiol, Cannabidivarin, Δ9-Tetrahydrocannabivarin, and Cannabigerol in Mouse Peripheral Tissues. insufficient PubMed 28343385
311
Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota. insufficient PubMed 36768709
312
Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation. insufficient PubMed 38889235
313
Design, synthesis, and biological profiling of fluorinated cannabidiol and cannabigerol derivatives as promising therapeutic agents. insufficient PubMed 41645347
314
Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives. insufficient PubMed 36397993
315
Phytocannabinoids as novel therapeutic agents in CNS disorders. insufficient PubMed 21924288
316
Cannabis Vaping: Existing and Emerging Modalities, Chemistry, and Pulmonary Toxicology. insufficient PubMed 34622654
317
Pre-puberty cannabichromene exposure modulates reproductive function via alteration of spermatogenesis, steroidogenesis, and eNOS pathway metabolites. insufficient PubMed 37396845
318
Genotoxicity of selected cannabinoids in human lymphoblastoid TK6 cells. insufficient PubMed 39172143
319
Development and validation of a fit-for-purpose UHPLC-ESI-MS/MS method for the quantitation of cannabinoids in different matrices. insufficient PubMed 36854205
320
Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. insufficient PubMed 37764262
321
Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models. insufficient PubMed 39769302
322
Effect of Quantitative Structural Properties and Drug Formulation in Four Cannabinoids (Cannabidiol, Cannabigerol, Cannabichromene, and Cannabinol) on Their Lymphatic Transport after Enteral Administration in Rats. insufficient PubMed 40611782
323
Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. insufficient PubMed 33395525
324
Natural Cannabichromene (CBC) Shows Distinct Scalemicity Grades and Enantiomeric Dominance in Cannabis sativa Strains. insufficient PubMed 37023389
325
Selected phytocannabinoids inhibit SN-38- and cytokine-evoked increases in epithelial permeability and improve intestinal barrier function in vitro. insufficient PubMed 38950639
326
Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors. insufficient PubMed 39457041
327
Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy Against Streptococcus and Staphylococcus. insufficient PubMed 39596719
328
Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: part 1 - continuous bivariate analysis. insufficient PubMed 35354487
329
Design and synthesis of amphiphilic cannabichromene derivatives with antimicrobial potential. insufficient PubMed 41202683
330
Targeting the antioxidant, antimicrobial and anti-inflammatory activity of non-psychotropic Cannabis sativa L.: a comparison with chemotype V. insufficient PubMed 41121423
331
Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review. insufficient PubMed 37514074
332
Spent Material Extractives from Hemp Hydrodistillation as an Underexplored Source of Antimicrobial Cannabinoids. insufficient PubMed 38927152
333
Antidepressant Effects of South African Plants: An Appraisal of Ethnobotanical Surveys, Ethnopharmacological and Phytochemical Studies. insufficient PubMed 35846999
334
Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing. insufficient PubMed 37697897
335
Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ8-tetrahydrocannabinol: case studies. insufficient PubMed 35799289
336
Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. insufficient PubMed 25542687
337
Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products. insufficient PubMed 40131178
338
Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents. insufficient PubMed 35303507
339
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. insufficient PubMed 31549358
340
Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies. insufficient PubMed 36280497
341
Indeterminacy of cannabis impairment and ∆9-tetrahydrocannabinol (∆9-THC) levels in blood and breath. insufficient PubMed 35585089
342
Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. insufficient PubMed 23894589
343
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. insufficient PubMed 25257544
344
Pharmacology of cannabinoids in the treatment of epilepsy. insufficient PubMed 28087250
345
Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy. insufficient PubMed 28109780
346
Medical use of cannabis. Cannabidiol: a new light for schizophrenia? insufficient PubMed 23109356
347
Molecular pathway and structural mechanism of human oncochannel TRPV6 inhibition by the phytocannabinoid tetrahydrocannabivarin. insufficient PubMed 37532722
348
The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. insufficient PubMed 22155112
349
Oxa-adamantyl cannabinoids. insufficient PubMed 33636308
350
Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. insufficient PubMed 28527758
351
Cannabinergic ligands. insufficient PubMed 12505686
352
Pharmacology of cannabinoid receptor ligands. insufficient PubMed 10469884
353
Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor. insufficient PubMed 27879006
354
The CB1 cannabinoid receptor in the brain. insufficient PubMed 9974174
355
CB1 Cannabinoid Receptor Signaling and Biased Signaling. insufficient PubMed 34500853
356
Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor. insufficient PubMed 30333554
357
Endocannabinoids and Their Pharmacological Actions. insufficient PubMed 26408156
358
Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity. insufficient PubMed 29355030
359
Synthetic Cannabinoids. insufficient PubMed 26132518
360
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery. insufficient PubMed 39828030
361
Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. insufficient PubMed 33811300
362
Computational Analysis of Dipyrone Metabolite 4-Aminoantipyrine As A Cannabinoid Receptor 1 Agonist. insufficient PubMed 31490743
363
Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? insufficient PubMed 20590557
364
Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review. insufficient PubMed 34050525
365
Endocannabinoid System: A Multi-Facet Therapeutic Target. insufficient PubMed 27086601
366
Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities. insufficient PubMed 31771126
367
The pharmacology of cannabinoid receptors and their ligands: an overview. insufficient PubMed 16570099
368
Latest advances in cannabinoid receptor agonists. insufficient PubMed 19939187
369
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. insufficient PubMed 19285266
370
Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications. insufficient PubMed 31461639
371
The endocannabinoid system: physiology and pharmacology. insufficient PubMed 15550444
372
Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse. insufficient PubMed 25967266
373
The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species. insufficient PubMed 31165913
374
Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. insufficient PubMed 16596773
375
Functional Selectivity at Cannabinoid Receptors. insufficient PubMed 28826535
376
Pharmacology of cannabinoid CB1 and CB2 receptors. insufficient PubMed 9336020
377
The Spicy Story of Cannabimimetic Indoles. insufficient PubMed 34684770
378
Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update. insufficient PubMed 27215781
379
Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present). insufficient PubMed 38886185
380
Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. insufficient PubMed 16678907
381
Cannabinoid CB2 receptor orthologues; in vitro function and perspectives for preclinical to clinical translation. insufficient PubMed 37349984
382
Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and their Therapeutic Potential. insufficient PubMed 36028971
383
The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins. insufficient PubMed 29980914
384
Structural requirements for cannabinoid receptor probes. insufficient PubMed 16596776
385
Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. insufficient PubMed 19152719
386
CB₂: therapeutic target-in-waiting. insufficient PubMed 22197668
387
Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders. insufficient PubMed 39264450
388
An overview of the cannabinoid type 2 receptor system and its therapeutic potential. insufficient PubMed 29794855
389
The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies. insufficient PubMed 20236042
390
What we know and do not know about the cannabinoid receptor 2 (CB2). insufficient PubMed 24877594
391
Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders. insufficient PubMed 40943579
392
Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection? insufficient PubMed 32471272
393
The enigmatic pharmacology of GPR55. insufficient PubMed 19233486
394
Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity. insufficient PubMed 35862111
395
Is GPR55 an anandamide receptor? insufficient PubMed 19647110
396
GPR55 - a putative "type 3" cannabinoid receptor in inflammation. insufficient PubMed 26669245
397
Cannabinoid receptor ligand bias: implications in the central nervous system. insufficient PubMed 27835801
398
GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? insufficient PubMed 20370712
399
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). insufficient PubMed 35083862
400
The Endocannabinoid System of Animals. insufficient PubMed 31527410
401
GPR55: a new member of the cannabinoid receptor clan? insufficient PubMed 17876300
402
Pharmacological characterization of GPR55, a putative cannabinoid receptor. insufficient PubMed 20298715
403
Cannabis and Endocannabinoid Signaling in Epilepsy. insufficient PubMed 26408165
404
Epilepsy, neuroinflammation and cannabidiol What do we know thus far? insufficient PubMed 41560741
405
Cannabinoids in Gynecological Diseases. insufficient PubMed 34676329
406
Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders. insufficient PubMed 42114685
407
An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors. insufficient PubMed 29098189
408
N-Acyl Amino Acids (Elmiric Acids): Endogenous Signaling Molecules with Therapeutic Potential. insufficient PubMed 29138268
409
The elmiric acids: biologically active anandamide analogs. insufficient PubMed 18187165
410
Endocannabinoids and nutrition. insufficient PubMed 18426507
411
N-acylethanolamines, anandamide and food intake. insufficient PubMed 19413995
412
Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. insufficient PubMed 20353771
413
Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. insufficient PubMed 19285259
414
Fatty acid amide hydrolase (FAAH) and the endocannabinoid system in obesity: Mechanistic insights and pharmacological opportunities beyond incretin-based therapies. insufficient PubMed 42144898
415
Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review. insufficient PubMed 30537148
416
Cannabinoid signalling. insufficient PubMed 16109430
417
Cannabinoids and anxiety. insufficient PubMed 21309120
418
Novel cannabinoid receptors. insufficient PubMed 17906678
419
TRPV1 Channel: A Potential Drug Target for Treating Epilepsy. insufficient PubMed 26411767
420
Endocannabinoid signaling in microglia. insufficient PubMed 36222019
421
Modulation of TRPV1 channel function by natural products in the treatment of pain. insufficient PubMed 32738201
422
Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems. insufficient PubMed 40684872
423
Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment. insufficient PubMed 31839498
424
Cannabis for the Treatment of Epilepsy: an Update. insufficient PubMed 30194563
425
Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies. insufficient PubMed 32091020
426
Beyond Cannabis: Plants and the Endocannabinoid System. insufficient PubMed 27179600
427
Cannabis y los sistemas exocannabinoide y endocannabinoide. Su uso y controversias. insufficient PubMed 31695229
428
Cannabidiol interactions with voltage-gated sodium channels. insufficient PubMed 33089780
429
Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids. insufficient PubMed 29240420
430
Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. insufficient PubMed 19070372
431
Pharmacogenetics of new analgesics. insufficient PubMed 20942817
432
A Systematic Review of Plant-Derived Natural Compounds for Anxiety Disorders. insufficient PubMed 26845556
433
Toward an effective peripheral visceral analgesic: responding to the national opioid crisis. insufficient PubMed 29470146
434
Potential Future Pharmacological Treatment of Bladder Dysfunction. insufficient PubMed 26990140
435
Mechanisms of Cell Death Induced by Cannabidiol Against Tumor Cells: A Review of Preclinical Studies. insufficient PubMed 40006844
436
TRPA1. insufficient PubMed 24756722
437
Molecular Targets of the Phytocannabinoids: A Complex Picture. insufficient PubMed 28120232
438
G-protein coupled receptors regulating cough. insufficient PubMed 21727026
439
Myrcene and terpene regulation of TRPV1. insufficient PubMed 31446830
440
Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward. insufficient PubMed 35605018
441
Effects of opioids, cannabinoids, and vanilloids on body temperature. insufficient PubMed 21622235
442
Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. insufficient PubMed 36150527
443
Metabolism of endocannabinoids. insufficient PubMed 27516570
444
Anandamide uptake explained? insufficient PubMed 22297258
445
Anandamide receptors. insufficient PubMed 12052051
446
Endocannabinoid metabolism by cytochrome P450 monooxygenases. insufficient PubMed 25461979
447
Endocannabinoids and pregnancy. insufficient PubMed 20302856
448
Anandamide and its metabolites: what are their roles in the kidney? insufficient PubMed 27100705
449
Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors. insufficient PubMed 32867595
450
Druggable Targets in Endocannabinoid Signaling. insufficient PubMed 32894511
451
Chemical probes of endocannabinoid metabolism. insufficient PubMed 23512546
452
Amygdala FAAH and anandamide: mediating protection and recovery from stress. insufficient PubMed 24325918
453
Endocannabinoid overload. insufficient PubMed 20952498
454
Endocannabinoid hydrolases. insufficient PubMed 12432941
455
Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases. insufficient PubMed 36966972
456
Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. insufficient PubMed 24676249
457
A fatty gut feeling. insufficient PubMed 23567058
458
Regulation of food intake by oleoylethanolamide. insufficient PubMed 15770421
459
The endocannabinoid and paracannabinoid systems in natural reward processes: possible pharmacological targets? insufficient PubMed 40274041
460
Brain molecules and appetite: the case of oleoylethanolamide. insufficient PubMed 23464987
461
Regulation of Cholesterol and Triglyceride Metabolism by Fatty acid Ethanolamides. insufficient PubMed 42068417
462
Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial. insufficient PubMed 31132422
463
Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain. insufficient PubMed 39714723
464
The search for the palmitoylethanolamide receptor. insufficient PubMed 15963531
465
Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases. insufficient PubMed 28215162
466
Cannabimimetic fatty acid derivatives in cancer and inflammation. insufficient PubMed 10785541
467
Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence. insufficient PubMed 33919499
468
Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD). insufficient PubMed 24602801
469
Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. insufficient PubMed 22697514
470
Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. insufficient PubMed 11945157
471
Oleamide: a member of the endocannabinoid family? insufficient PubMed 14691053
472
Oleamide: a fatty acid amide signaling molecule in the cardiovascular system? insufficient PubMed 17445087
473
The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? insufficient PubMed 10469890
474
The role of the CB1 receptor in the regulation of sleep. insufficient PubMed 18514375
475
The enzymatic inactivation of the fatty acid amide class of signaling lipids. insufficient PubMed 12505696
476
Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. insufficient PubMed 10197045
477
N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities. insufficient PubMed 29082315
478
The cannabinoid receptors. insufficient PubMed 12432948
479
Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. insufficient PubMed 22959887
480
A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development. insufficient PubMed 21810478
481
Role of anorectic N-acylethanolamines in intestinal physiology and satiety control with respect to dietary fat. insufficient PubMed 24681513
482
Gene Expression of Endocannabinoid System Components in Skeletal Muscle and Adipose Tissue of South Asians and White Caucasians with Overweight. insufficient PubMed 30070030
483
Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. insufficient PubMed 11463796
484
Roles of fatty acid ethanolamides (FAE) in traumatic and ischemic brain injury. insufficient PubMed 24874648
485
Lipidomic Analysis of Endocannabinoid Signaling: Targeted Metabolite Identification and Quantification. insufficient PubMed 26839710
486
Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. insufficient PubMed 23813098
487
Cannabinoids and Sleep/Wake Control. insufficient PubMed 33537938